Document:

Amended and Restated Master Services Agreement

 Exhibit 10.3 
  
 

 
  
 AMENDED AND RESTATED

  
 STRATEGIC MASTER SERVICES AGREEMENT 
  
 THIS AMENDED AND RESTATED STRATEGIC MASTER SERVICES AGREEMENT (“Agreement”)
is effective as of 10th day of February, 2004, by and between CATO RESEARCH LTD., a North Carolina corporation (“CRL”), and the undersigned client, DUSKA SCIENTIFIC CO., a Pennsylvania corporation (“CLIENT”).

  
 WHEREAS, CLIENT is engaged in the development of
CLIENT’s adenosine 5’-triphosphate-based formulation for the diagnosis of bradycardia as the cause of syncope (“Product”); and 
  
 WHEREAS, CRL is in the business of providing services for development of the Product within and outside of the United States; and 
  
 WHEREAS, CLIENT desires to engage CRL, and CRL desires to be engaged
by CLIENT for the purpose of assisting CLIENT with certain aspects of the development of Product, specifically a Phase 2 study of Product (the “Phase 2 ATPaceTM Study”) and a Phase 3 study of Product (the “Phase 3 ATPaceTM Study”); and 
  
 WHEREAS, CLIENT is seeking to raise the funding necessary to perform and finance the Phase 2 ATPaceTM Study and the Phase 3 ATPaceTM Study in an equity offering; 
  
 WHEREAS, CLIENT in connection with its seeking equity financing plans
to become a wholly-owned subsidiary of Shiprock, Inc., a Nevada corporation, in a reverse triangular merger, with Shiprock, Inc. thereafter being named Duska Therapeutics, Inc. (the “Parent Corp.”); and 
  
 WHEREAS, CLIENT and CRL previously entered into a Master Services
Agreement, dated as of February 10, 2004 (the “Prior Agreement”), which they wish to amend, restate and replace in its entirety. 
  
 Now, therefore, in consideration of the mutual promises, benefits, rights, and obligations set forth below, the parties agree as follows: 
  
 1. Services. It is the intent of CLIENT and CRL to enter into a preferred-provider
relationship with respect to all phases of the development of the Product, including, but not limited to, the Phase 2 ATPaceTM Study, the Phase 3 ATPaceTM Study and all necessary studies, reports, analyses, meetings and any other services required or appropriate to obtain regulatory approval of the
Product worldwide. To this end, the parties agree that concurrently with the execution of this Agreement, they shall execute a schedule (the “Description of Services”) that sets forth the services CLIENT requests CRL to perform, and the
services CRL hereby agrees to perform, in connection with the Phase 2 ATPaceTM Study and the Phase 3 ATPaceTM Study (collectively, the “Services”) and that CLIENT shall pay CRL for the Services in accordance with the fee amounts and fee structure set forth in the Description of Services, which both parties agree is a
fair and reasonable compensation arrangement for the Services described therein. The Description of Services amends and supersedes in full Exhibit A-1 of the Prior Agreement and is subject to all of the terms and conditions of this Agreement. In
addition, with respect to the development of the Product but outside the scope of the Services described in the Description of Services, CLIENT agrees to provide CRL with the opportunity to render any of the services set forth in the Description
of Services hereto as needed by CLIENT from time to time, which services are the services CRL regularly performs for its clients, on terms and conditions to be mutually agreed upon by CRL and CLIENT. With respect to the Services, the fee amounts
set forth in the Description of Services will not be increased during the term of this Agreement and are inclusive of all overhead and other expenses of CRL, except for the reimbursement of CRL’s out-of-pocket expenses, as set forth in
Exhibit C. CRL hereby agrees to undertake the Services as reasonably requested by CLIENT during the term of this Agreement in accordance with Paragraph 2 hereof. CLIENT and CRL acknowledge that the Services to be provided are based on
protocols that have not yet been approved by the FDA and that revisions to those protocols could result in material revisions to the services required by CLIENT. CRL and CLIENT agree to work in good faith to revise the description of the Services
set forth in the Description of Services to reflect any changes in the protocols, which revision may include adjustments to the fees to be paid for the Services; provided however, that the percentage of the fees for Services that is to be paid in
CLIENT’s stock, the conditions 

  

 Page 1 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 
under which such fees are to be paid in stock and the valuation of such stock shall continue to be as set forth in Exhibits B-1 and B-2.

  
 2. Request for Out of Scope Services. 
  
 2.1 At any time CLIENT needs CRL to perform any CRL services set forth in the
Description of Services and not included in the Services (as set forth in the Description of Services) (in each case, “Out of Scope Services”), CLIENT’s Authorized Representative (as described in Paragraph 17 herein) shall contact
CRL’s Authorized Representative (as described in Paragraph 17 herein) and provide CRL with sufficient information to permit CRL to understand the work effort being requested. Included within this information shall be any time limitations or
other constraints to be placed on the project. CRL shall have ten (10) working days to review the information provided and to notify CLIENT if such time limitations or other constraints are acceptable. If acceptable, each request for Out of Scope
Services shall be submitted in writing by CRL to CLIENT in the form of a Work Order Request, as illustrated in Exhibit A attached hereto (“Work Order Request”). Work Order Requests are referred to in this Agreement as a “Work
Package.” CLIENT shall have ten (10) working days to review, authorize and return an executed copy of each Work Package to CRL. Each such authorized Work Package shall be appended to and shall become a part of this Agreement. If the Work
Package is not authorized and returned to CRL within ten (10) working days, CRL shall be under no obligation to perform the Services specified in the Work Package. 
  
 2.2 In the event that either (a) time limitations or other constraints are not acceptable to CRL or (b) the resulting
estimated expenses or other constraints as indicated in the Work Package are not acceptable to CLIENT, the Authorized Representatives of CLIENT and CRL shall attempt to establish mutually acceptable alternatives. If acceptable alternatives are
reached, they shall be recorded in a new Work Package that shall be executed and delivered by both parties. If CLIENT and CRL are unable to agree on the terms of the Work Package, CLIENT shall be permitted to obtain the desired services from a third
party without any liability to CRL. 
  
 3. Specification for Services.

  
 3.1 CRL shall undertake all work pursuant to the mutually
agreed-upon specifications, instructions, or guidelines as may be described in the authorized Description of Services or each Work Package as the case may be. In the case of a Work Package, it shall be CLIENT’s responsibility to ensure that the
authorized Work Package specifies all methods, requirements, and obligations related to the Out of Scope Services to be performed under that Work Package . In the event any authorized Work Package is unclear, ambiguous, or permits the end result to
be created in different ways, CRL shall use reasonable efforts to interpret and resolve any ambiguities prior to undertaking the Out of Scope Services set forth in the Work Package (including, without limitation, notifying CLIENT in writing of such
ambiguity before commencing the services), provided however, that any Out of Scope Service undertaken according to such a deficient Work Package shall be accepted and paid for by CLIENT, even if the end result of such Out of Scope Service varies
from that anticipated by CLIENT. 
  
 3.2 CLIENT or CRL may request
a change in any Work Package by providing written notification that specifies any such change(s) to the other party, whereupon the Authorized Representative of each of CRL and CLIENT shall review such request and attempt to agree upon the changes to
be implemented. If the parties’ Authorized Representatives reach an agreement regarding the proposed changes, CRL shall submit to CLIENT a revised Work Package related to the requested Out of Scope Services. If the parties’ Authorized
Representatives are unable to agree on a proposed change or proposed changes to the Work Package, the original Work Package shall control unless one of the parties terminates such Work Package pursuant to Paragraph 5, provided that CLIENT shall be
responsible for payment to CRL at rates that shall be agreed to by CLIENT and CRL for any Out of Scope Services performed (in whole or in part) in accordance with CLIENT’s verbal instructions and a verbal agreement to change the Work Package.

  
 4. Compensation. As full and complete compensation for all Services
provided by CRL and for all obligations assumed by CRL hereunder, CLIENT agrees to pay CRL in the amounts set forth in the Description of Services (“Compensation”) and in accordance with the special compensation arrangements set
forth in Exhibit B-1 with respect to the Phase 2 ATPaceTM Study, and in Exhibit B-2 with respect to a Phase 3 ATPaceTM Study, each of which is attached to this Agreement and made a part hereof. If, after the date of this Agreement, CLIENT requests CRL to provide Out of Scope Services under this
Agreement, including, without limitation, Services relating to CLIENT’s 

  

 Page 2 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 
ATPaceTM Phase 1b development program that are not covered by the Master Services Agreement, dated as of April 1, 2002, CRL’s compensation for such requested Out of Scope Services shall be
reflected in a separate Work Package prepared by CRL and signed by CLIENT and CLIENT shall pay CRL for all such Out of Scope Services in cash or otherwise as CLIENT and CRL shall agree. The billing arrangement for each Work Package shall be
specified using a completed Work Package related to the requested Out of Scope Services. Amounts reflected in CRL’s invoices to CLIENT for Services and Out of Scope Services rendered pursuant to this Agreement and/or any Work Package shall be
due upon receipt of such invoices. Payments that are not received within thirty (30) days after the date of invoice shall accrue interest at the rate of 1.25% per month from the date of the invoice. 
  
 5. Term and Termination. 
  
 5.1 This Agreement shall last until the completion or termination of the
Phase 3 ATPaceTM Study, unless terminated earlier
as set forth below, provided, however, that if the term of an authorized Work Package extends beyond the term of the Agreement, the Agreement will continue in effect until the completion of the Work Package, or in the case of an early termination of
a Work Package, until CRL has performed ordinary-course wind-down Out of Scope Services in connection with such termination. 
  
 5.2 Each party shall have the right and opportunity to terminate this Agreement or any Work Package based on the default of the other party to comply with
any material terms of this Agreement, provided that the terminating party is not itself in material default of this Agreement and further that the defaulting party has been given not less than thirty (30) days prior written notice of the material
default and the opportunity to cure the material default during such period. 
  
 5.3 If termination of this Agreement or a Work Package is due to a material default not cured by CRL, CLIENT’s continuing obligation to CRL shall be limited to payment pursuant to the Description of
Services, Exhibit B-1, Exhibit B-2, and/or one or more outstanding Work Packages, as the case may be, of those costs and expenses already incurred by and owed to CRL up to the date of termination, and shall exclude any winding down
expenses of CRL. With respect to the Services, or if a Work Package specifies a fixed fee for Out of Scope Services, CRL shall retain any fees already paid to CRL and CLIENT shall pay CRL for all Services and/or Out of Scope Services rendered, but
not yet paid in the amounts specified in the Description of Services and/or a Work Package, and pursuant to the special compensation arrangements set forth in Exhibit B-1, Exhibit B-2 or an authorized Work Package, as the case
may be. CLIENT shall, however, retain any rights that it may have for damages or otherwise resulting from CRL’s default. 
  
 5.4 If termination of the this Agreement or a Work Package is due to a material default not cured by CLIENT, CRL shall be entitled to retain all payments
made, including the pro rata amount of CLIENT’s securities earned through the effective date of termination pursuant to Exhibit B-1 and/or Exhibit B-2, as the case may be, and shall be entitled to payment for those costs and
expenses incurred by CRL and not yet paid for by CLIENT up to and including the date of termination. With respect to the Services and if any Work Package specifies a fixed fee for Out of Scope Services, CLIENT shall pay CRL for all Services and/or
Out of Scope Services rendered, but not yet paid in the amounts specified in the Description of Services and/or a Work Package, and in accordance with the special compensation arrangements set forth in Exhibit B-1, Exhibit B-2 or an
authorized Work Package, as the case may be. 
  
 5.5 Each
party shall also have the right to terminate this Agreement or any Work Package for any reason upon ninety- (90) days’ prior written notice to the other party. CRL shall be entitled to retain all payments made pursuant to this Agreement or any
Work Package, including the pro rata amount of CLIENT’s securities earned through the effective date of termination pursuant to Exhibit B-1 and/or Exhibit B-2, as the case may be, and shall be entitled to payment for those costs
and expenses incurred by CRL up to and including the effective date of termination based on the amounts specified in the Description of Services or a Work Package as the case may be, and in accordance with the special compensation
arrangements set forth in Exhibit B-1, Exhibit B-2 or one or more Work Packages, as the case may be. If the Work Package specifies a fixed fee for Services, CLIENT shall pay CRL for all Services rendered, but not yet paid in the
amounts specified in the Work Package, and in accordance with the special compensation arrangements set forth in Exhibit B-1, Exhibit B-2 or Work Package, as the case may be. In addition to all other amounts due, if CLIENT is the party
terminating this Agreement (except for cause), the Phase 2 ATPaceTM Study, Phase 3 ATPaceTM Study or Work 

  

 Page 3 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 
Package(s) (other than pursuant to the last sentence of Paragraph 5.8) as the case may be, CLIENT shall, at its option, either (a) pay CRL twenty percent
(20%) of the estimated remaining unbilled amounts for the Phase 2 ATPaceTM Study, if any, the Phase 3 ATPaceTM Study, if any and any outstanding Work Package(s) from the date of the notice of termination within thirty (30) days of the effective date of termination, or (b) submit, within six (6) months of the effective date of
termination, a request for post-termination Out of Scope Services (“Post-termination Out of Scope Services”) of equivalent or greater value than the terminated portion of the Phase 2 ATPaceTM Study, Phase 3 ATPaceTM Study and Work Package(s), provided, however, that if CRL notifies CLIENT that such
proposed Post-termination Out of Scope Services are not acceptable to CRL or if CLIENT does not authorize the Work Package for such Post-termination Out of Scope Services within ten (10) days following submission of such Work Package by CRL to
CLIENT, CLIENT shall be obligated to pay CRL the amount set forth in option (a) above. 
  
 5.6 Notwithstanding any of the foregoing to the contrary, in the event that (a) within one (1) year of a Change of Control, either (i) CLIENT terminates this Agreement under Paragraph 5.5, or (ii) CRL terminates this
Agreement as a result of a material default of CLIENT that constitutes a de facto termination (as defined below) of this Agreement by CLIENT, or (b) CLIENT grants a license to (or sells) the Product to a third party that becomes responsible
for conducting the Phase 2 ATPaceTM Study or Phase
3 ATPaceTM Study and CRL is not engaged within
ninety (90) days thereof by the licensee (or purchaser) of the Product to perform substantially the Services for the licensee (or purchaser) with respect to the Product on substantially similar terms as CRL would have performed for CLIENT under this
Agreement if the Product had not been licensed (or sold) (any such event under clause (a) or clause (b) being a “Special Termination Event”), then CLIENT agrees to pay CRL the following special termination fee: CLIENT shall compensate CRL
for all Services actually performed under this Agreement prior to the Special Termination Event in accordance with Paragraph 4, and shall compensate CRL for wind down work in accordance with Paragraph 5.7, and in addition shall pay CRL the lesser of
(p) 25% of the Budgeted Amount for remaining Services by CRL on the Product from the termination date through the end of the Phase 2 ATPaceTM Study if the Special Termination Event occurs prior to commencement of the Phase 3 ATPaceTM Study or (b) the filing of the ATPaceTM New Drug Application if the Special Termination Event occurs after commencement of the
Phase 3 ATPaceTM Study, or (q) $250,000.

  
 For purposes of this Paragraph, CLIENT and CRL agree

  
 (x) a “Change of Control” shall exist in any of the
following circumstances: 
  

	 	(a)	the acquisition, directly or indirectly, in a transaction or a series of related transactions by any person or related group of persons (other than CLIENT or a person that directly
or indirectly controls, is controlled by, or is under common control with, CLIENT) of beneficial ownership (within the meaning of Rule 13d-3 of the Securities Exchange Act of 1934, as amended) of securities possessing more than fifty percent (50%)
of the total combined voting power of CLIENT’s outstanding securities; 

  

	 	(b)	a change in the composition of the Board over a period of thirty-six (36) consecutive months or less such that a majority of the Board members ceases to be comprised of individuals
who have been Board members continuously since the beginning of such period; 

  

	 	(c)	a merger or consolidation, other than a merger or consolidation of Parent Corp. and CLIENT, in which securities possessing at least fifty percent (50%) of the total combined voting
power of CLIENT’s outstanding securities are transferred to a person or persons different from the persons holding those securities immediately prior to such transaction and any series of related events leading up to that transaction; or

  

	 	(d)	the sale, transfer or other disposition of all or substantially all of CLIENT’s assets to another entity or the distribution of substantially all of CLIENT’s assets upon
the dissolution of CLIENT. 

  

 Page 4 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 (y) “De facto” termination by CLIENT shall mean that CLIENT takes action that
prevents or significantly inhibits CRL from performing Services, materially defaults in payment of CRL’s compensation under this Agreement, fails to materially perform its obligations under this Agreement, ceases to request Services, or without
warrant therefor claims material breach by CRL of this Agreement or undertakes an investigation of CRL’s Services, in each case, with respect to the Product. 
  
 (z) “Budgeted Amount” shall be the amount set forth in the Description of Services for Services with respect to
the Product through the completion of the Phase 3 ATPaceTM Study. 
  
 CLIENT and CRL agree that the payment of
the special termination fee upon a Special Termination Event is neither liquidated damages nor a penalty but rather is specifically offered by CLIENT to CRL and accepted by CRL as consideration for CRL’s risk related to its agreement to take a
significant portion of the Budgeted Amount of compensation for the Services in the form of CLIENT’s securities in lieu of cash compensation, which securities, upon issuance to CRL, will be subject to restrictions on transferability and of
uncertain value. CLIENT and CRL further agree that CRL’s right to payment under this Paragraph shall be in addition to any other remedy available to CRL upon breach of this Agreement by CLIENT; provided, however, if CRL is entitled to payment
under this Paragraph, such payment shall be in lieu of any payment required to be made by CLIENT, upon breach of this Agreement to CRL for lost profits (but not actual damages). 
  
 5.7 Upon notice of termination from CLIENT or the occurrence of a Special Termination Event, CRL shall immediately cease
work and cease incurring costs in connection with the terminated Phase 2 ATPaceTM Study, Phase 3 ATPaceTM Study or Work Package(s), as the case may be; and CRL shall inform CLIENT of the extent to which performance has been completed through the anticipated time for termination; and CRL shall, (unless directed to do
otherwise by CLIENT in the case of a termination by CLIENT), immediately take steps to wind down work in progress in an orderly fashion during the notice period. CLIENT shall pay CRL in amounts consistent with those in the Description of Services
or the applicable Work Package, for all reasonable and customary wind down Services and/or Out of Scope Services following CLIENT’s notice of termination and prior to the effective date of such termination. If CLIENT (or a licensee or
purchaser of the Product) abandons the Phase 2 ATPaceTM Study or Phase 3 ATPaceTM Study or a Work Package due to termination of the development of the Product or a decision to substantially revise the Product development program, no further amounts will be owed to CRL for Services or Out of Scope
Services rendered after the date of termination or under Paragraphs 5.5 or 5.6, notwithstanding any other provision of this Agreement to the contrary. 
  
 6. Location of Services. CRL shall perform the Services at CRL’s facilities, or at such other places as may be mutually agreed upon by CRL’s and
CLIENT’s Authorized Representatives. 
  
 7. Confidentiality.

  
 7.1 Both parties agree that certain information transmitted to
implement the Services or any Out of Scope Services rendered under this Agreement is confidential in nature (“Confidential Information”). CLIENT shall mark all Confidential Information as such prior to providing it to CRL. Confidential
Information also shall include information that CLIENT orally provides to CRL, provided that within fifteen (15) days thereafter, CLIENT specifies in writing to CRL that such information is confidential. Confidential Information shall be held in
confidence by CRL, and not disclosed to third parties for five (5) years after the date the information is transmitted. It is understood, however, that Confidential Information shall not include, and the obligations of confidentiality and non
disclosure shall not apply to, information that: (a) is or becomes publicly available through no fault of CRL; or (b) is disclosed to CRL, without confidentiality restrictions, by a third party entitled to disclose it; or (c) is known to CRL prior
to its disclosure by CLIENT to CRL; or (d) is developed independently by CRL without the use of CLIENT Confidential Information; or (e) is information generally known by persons in the same field of business as CRL. 
  
 7.2 CRL shall use the Confidential Information furnished by CLIENT only for
the purpose of fulfilling CRL’s obligations under this Agreement. Upon completion of the Services or any Out of Scope Services requested that use the Confidential Information, or upon earlier termination of this Agreement, CRL shall, when
requested by CLIENT in writing, promptly return to CLIENT all of the materials provided by CLIENT and containing Confidential 

  

 Page 5 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 
Information, with the exception that one (1) copy may be retained by CRL solely for recordkeeping purposes. 
  
 7.3 CRL shall not disclose, without the prior written consent of CLIENT, any
CLIENT Confidential Information to any third party other than CRL’s employees who have a need to know such information, hospital authorities, Institutional Review Board members, clinical investigators, and others who must be involved in the
Services or any Out of Scope Services and who, in each case, need to know such information for the purposes of the Services or Out of Scope Services. CRL agrees that it shall take commercially reasonable steps to prevent the disclosure or use of any
such Confidential Information by CRL’s principals, officers, employees, or agents except as provided herein. All obligations of confidentiality and nondisclosure set forth in this Agreement shall survive the expiration or earlier termination,
for any reason, of this Agreement for the time period specified in Paragraph 7.1 hereof. 
  
 7.4 In the event that any Confidential Information is required to be disclosed by CRL to any government or regulatory authority or court entitled by law to disclosure of the same, CRL shall promptly notify CLIENT when
such requirement to disclose has arisen, and CRL shall cooperate with CLIENT so as to enable CLIENT to: (a) seek an appropriate protective order; (b) make the confidential nature of the Confidential Information known to such governmental or
regulatory authority or court; and (c) make any applicable claim of confidentiality in respect of the Confidential Information. 
  
 7.5 For purposes of this Agreement, the parties hereby acknowledge and agree that the terms of this Agreement and the contents of the Exhibits hereto and
all Work Packages hereunder, and the results of Services rendered pursuant to this Agreement, shall be considered Confidential Information. 
  
 7.6 Both parties recognize that the Federal Health Insurance Portability and Accountability Act of 1996 and implementing regulations (collectively,
HIPAA”) require written confidentiality agreements to protect the privacy and security of protected health information (as defined under HIPAA), that may be acquired in the course of performing this Agreement. The parties agree to maintain the
confidentiality of protected health information to the extent required by applicable law. Additionally, the parties agree to enter into such confidentiality agreements, as may be required by HIPAA and other applicable state and/or federal laws
relating to the privacy and security of protected health information. 
  
 8.
Ownership. 
  
 8.1 Except as otherwise set forth in
this Paragraph 8, all materials supplied to CRL by CLIENT shall be the sole and exclusive property of CLIENT. CLIENT shall have the full and free right to use all such materials in any way deemed by CLIENT to be necessary or advisable either
directly, or through agents, or otherwise, without payment to CRL except as specified under Paragraph 4. Ownership of all materials prepared or developed by CRL for CLIENT or on behalf of CLIENT and directly related to the Services or any Out of
Scope Services rendered pursuant to this Agreement (except for CRL-developed computer software or CRL proprietary information) shall become the sole and exclusive property of CLIENT only after the receipt by CRL of “Compensation” as
defined in Paragraph 4. CRL shall promptly deliver to CLIENT copies of all materials that are generated by or come into CRL’s possession in the performance of Services or Out of Scope Services. 
  
 8.2 Except as necessary for the provision of Services or Out of Scope
Services by CRL in accordance with this Agreement, nothing in this Agreement, nor the delivery by CLIENT, or by any third party involved in the subject matter of the Services or Out of Scope Services, of any information or materials to CRL, shall be
deemed to grant to CRL any right or license under any Confidential Information, patents, patent applications, know-how, technology, inventions or other intellectual property of CLIENT. 
  
 8.3 Pursuant to obligations set forth in Paragraph 4 and the above, title to all inventions, discoveries, improvements,
data, and information, whether or not any of these are patentable, and all copyrightable works resulting from the performance of and directly related to the Services or Out of Scope Services shall be transferred to CLIENT immediately and
automatically upon receipt by CRL of the full Compensation specified in this Agreement. CRL agrees to furnish and execute any additional documents as CLIENT may require to establish CLIENT’s ownership of such rights on the condition that if CRL
is required to provide any assistance in the preparation of such documents after the expiration or termination of the applicable Services or Out of Scope Services or if 

  

 Page 6 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 
compensation for such assistance is not included in the applicable Work Package, then CLIENT shall pay CRL at CRL’s standard rate at that time for any
such assistance. 
  
 8.4 CLIENT acknowledges that during
CRL’s performance of the Services and Out of Scope Services, CRL may prepare or develop certain materials designed to assist in its provision of Services and Out of Scope Services under this Agreement, but not intended to be provided to CLIENT
as a deliverable under this Agreement. Such materials include but are not limited to, data management software, data management tools and trial tracking software. CLIENT also acknowledges that during CRL’s performance of the Services or Out of
Scope Services, CRL may develop certain analytical skills, prepare certain methods of analysis, develop or discover certain trade secrets and acquire certain general knowledge that relate directly to CRL’s business of providing clinical
research services to third parties and not to specific medical technologies, products or devices. Except to the extent such materials, skills, methods, analysis, trade secrets, or knowledge are specifically incorporated in the deliverables of the
Services or Out of Scope Services, they shall be the exclusive property of CRL; and to the extent they are incorporated in the deliverables of the Services or Out of Scope Services, only non-exclusive rights shall transfer to CLIENT and only as to
the physical embodiment of the skill, method, analysis, secret, or knowledge and then only in accordance with the terms of this Paragraph 8. 
  
 9. Representations. 
  
 9.1 CRL hereby represents that it has the experience, capability, and resources, including, but not limited to, sufficient personnel and supervisors, to
perform the Services and Out of Scope Services under any authorized Work Package in a commercially reasonable manner and CRL further represents that it shall at all times devote the necessary personnel and supervisors to perform the Services and Out
of Scope Services in a competent manner. CRL represents and warrants that no employee or person working under supervision of CRL in providing Services and Out of Scope Services under this Agreement has been debarred or convicted of any crimes
pursuant to the U.S. Food, Drug and Cosmetic Act and will immediately give CLIENT notice of any such debarment or conviction or proceeding proposing any such action that arises during the term of this Agreement. 
  
 9.2 CLIENT hereby represents and warrants that it owns all right, title, and
interest in and to, or has obtained full and sufficient right and authority, to use in the manner contemplated by this Agreement, any materials, information, data or documentation furnished by CLIENT to CRL in connection with CRL’s performance
of the Services or any Out of Scope Services. Without limiting the foregoing, CLIENT specifically warrants to CRL that CLIENT has obtained valid licenses or other legal rights as needed for CRL to use all third party materials, information, data,
and documentation provided by CLIENT to CRL. 
  
 9.3 CLIENT also
represents and warrants that it will have the ability to comply with and perform all financial obligations set forth in this Agreement once it authorizes CRL to commence work under this Agreement and each Work Package following its authorization of
that Work Package. 
  
 10. CRL’s Personnel. 
  
 10.1 CRL is responsible for all aspects of the labor relations of its
personnel, including, but not limited to wages, benefits, discipline, hiring, firing, promotions, pay raises and overtime, as well as job and shift assignments, and for assuming that all such actions are in compliance with applicable law. CLIENT
shall have no power or authority in these areas. CRL agrees to pay, and CRL accepts full and exclusive liability to pay, all contributions and taxes imposed by any federal or state governmental authority, with respect to or measured by wages,
salaries, or other compensation paid by CRL to persons employed by CRL. 
  
 10.2 CLIENT understands that the performance of the Services and Out of Scope Services under this Agreement requires special skills, training and experience. CLIENT further understands that CRL has expended considerable sums in the training
of its personnel to perform the Services and Out of Scope Services, availed them access to experienced and highly skilled practitioners at CRL to enable such personnel to acquire new skills and develop existing skills, and provided opportunities to
such personnel to gain valuable experience in performing services of the type called for in this Agreement. CLIENT understands that if it were to employ a CRL employee, CLIENT would acquire the advantages of such skills, training and experience.
Therefore, CLIENT agrees that if, during the term of this Agreement or within the three-month period commencing with the date of termination of this Agreement, CLIENT, directly or indirectly through a parent or subsidiary, employs or solicits and
subsequently employs, 

  

 Page 7 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 
whether as an employee or independent contractor, any person who is or was employed by CRL during the term of this Agreement, then CLIENT will pay CRL a
one-time fee of one-third of the annual base salary of such person while employed at CRL calculated as of the date such person’s employment with CRL terminated, or, if earlier, the date of termination of this Agreement. 
  
 11. Indemnification. 
  
 11.1 CLIENT shall indemnify and defend and hold harmless CRL, affiliated companies of CRL, and the officers, directors, and
employees of CRL, from and against all liability, loss, costs, claims, damages, expenses, judgments, awards, and settlements as well as attorneys’ fees and expenses (whether or not these are covered by insurance), whether in tort or in
contract, law or equity, that may be incurred by reason of or arising out of any claim made by any third party, with respect to the provision of Services and Out of Scope Services by CRL in accordance with this Agreement, including without
limitation any claim made by a third party: (a) regarding the use or publication by CLIENT of any results of studies produced by CRL or data, materials, or work product delivered to CLIENT pursuant to a this Agreement; (b) regarding CLIENT’s
use or development of any Products being tested under the Agreement; (c) regarding infringement of or related to any intellectual property or proprietary rights of a third party in relation to materials, data, or other information furnished by or on
behalf of CLIENT; (d) resulting or arising from compliance by CRL with instructions provided by or on behalf of CLIENT; or (e) resulting or arising from any breach of CLIENT’s warranties hereunder; provided, however, that this indemnification
shall not extend to any claims arising out of : (f) any breach by CRL of the terms of this Agreement; (g) the negligent or willful failure of CRL, its officers, agents or employees, to comply with any applicable law or other government requirement;
or (h) the gross negligence or willful malfeasance of CRL, its officers, agents or employees or any third-party person or entity engaged by CRL on behalf of CLIENT to perform Services or Out of Scope Services for CLIENT under this Agreement, unless,
in the case of a third-party person or entity, the engagement of such third-party person or entity was approved in writing in advance by CLIENT. 
  
 11.2 Indemnification shall include all costs, including actual attorneys’ fees and expenses reasonably incurred in pursuing indemnity claims under or
in enforcement of this Agreement. 
  
 12. Insurance. 
  
 12.1 CLIENT shall provide and maintain in full force and effect, at no cost
to CRL, affiliated companies or CRL, and the officers, directors and employees of CRL and affiliated companies of CRL (collectively, “CRL Insureds”), customary insurance coverage for all Services and Out of Scope Services, including, but
not limited to, phases of clinical trials and use of Products developed under this Agreement in any clinical trial or otherwise, including, without limitation, errors and omissions, products liability, general liability, and related insurance
coverage, with per-occurrence policy limits in an amount not less than $3,000,000. Upon completion of each clinical trial for which CRL provides(ed) Services or Out of Scope Services to CLIENT during the term of this Agreement (each an
“Agreement Clinical Trial”), CLIENT shall also provide and maintain in full force and effect, at no cost to the CRL Insureds, an extended reporting policy (a “tail policy”) for a term of not less than two (2) years after
completion of each Agreement Clinical Trial, which tail policies shall cover claims first made and/or reported after completion of any such Agreement Clinical Trial. 
  
 12.2 CLIENT’s insurance policy(ies) shall: (a)name the CRL Insureds as additional insureds at no cost to the CRL
Insured; and (b) indicate that the policy will not be canceled or changed until thirty (30) days after written notice of such cancellation or change is delivered to CRL. CRL shall maintain in full force and effect, at no cost to CLIENT, customary
insurance coverage for all Services and Out of Scope Services consisting of workers’ compensation, comprehensive automobile liability and commercial general liability insurance (including errors and omissions insurance in an amount not less
than $3,000,000), and this insurance shall be considered primary insurance and not contributory with any similar insurance maintained by CLIENT. CRL shall provide CLIENT with evidence that the foregoing insurance is being maintained. 
  
 13. Limitation of Liability. EXCEPT AS SET FORTH IN THIS AGREEMENT, CRL MAKES NO
WARRANTY EITHER EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AS TO ANY MATTER, INCLUDING BUT NOT LIMITED TO, THE SERVICES, REPORTS, ANALYSES, DOCUMENTS, MEMORANDA, OR OTHER MATTER PRODUCED OR
PROVIDED UNDER THIS AGREEMENT. CLIENT AGREES THAT 

  

 Page 8 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 
REGARDLESS OF THE FORM OF ANY CLAIM, CLIENT’S SOLE REMEDY AND CRL’S SOLE OBLIGATION WITH RESPECT TO ANY CLAIMS MADE RELATED TO OR ARISING OUT OF
THIS AGREEMENT SHALL BE GOVERNED BY THIS AGREEMENT, AND IN ALL CASES CLIENT’S REMEDIES SHALL BE LIMITED SPECIFICALLY TO, AT CRL’S OPTION, CORRECTION OF THE SERVICES OR REIMBURSEMENT OF PAYMENTS MADE FOR THE SERVICES UNDER THE APPLICABLE
WORK PACKAGE DURING THE THREE (3) MONTH PERIOD IMMEDIATELY PRECEDING THE OCCURRENCE OF THE EVENT FOR WHICH THE CLAIM IS MADE. IT IS EXPRESSLY AGREED THAT IN NO EVENT SHALL CRL OR ANYONE ELSE WHO HAS BEEN INVOLVED IN THE PERFORMANCE OF THIS AGREEMENT
ON BEHALF OF CRL, INCLUDING ITS EMPLOYEES, AGENTS, REPRESENTATIVES, OR SUBCONTRACTORS, BE LIABLE FOR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL, OR EXEMPLARY DAMAGES ARISING FROM BREACH OF WARRANTY, BREACH OF CONTRACT, NEGLIGENCE, OR ANY OTHER
LEGAL THEORY, WHETHER IN DELICT/TORT OR CONTRACT, EVEN IF CRL HAS BEEN APPRISED OF THE LIKELIHOOD OF SUCH DAMAGES OCCURRING, INCLUDING WITHOUT LIMITATION DAMAGES FROM INTERRUPTION OF BUSINESS, LOSS OF PROFITS OR BUSINESS OPPORTUNITIES, LOSS OF USE
OF SOFTWARE, LOSS OF DATA, COST OF RECREATING DATA, LOSS DUE TO INTRODUCTION OF COMPUTER VIRUSES, COST OF CAPITAL, OR LOSSES CAUSED BY DELAY. 
  
 14. Force Majeure. In the event that CRL shall be delayed in, or hindered in, or prevented from the performance of any act required under this Agreement by reason
of strike, lockout, labor problems (including illness of key personnel), restrictions of government, judicial orders or decrees, riots, insurrection, terrorism, war, acts of God, inclement weather, or other causes that are beyond the reasonable
control of CRL, then performance of such act shall be excused until the cause is remedied. 
  
 15. Independent Contractor. CRL shall perform this Agreement as an independent contractor and not as CLIENT’s agent or employee. Neither party has any authority to make any statement, representation, or
commitment of any kind to take any action binding on the other party without the other party’s prior written authorization. 
  
 16. Use of CLIENT’s Name. CLIENT agrees that CRL may use CLIENT’s name as a reference for prospective clients or in professional literature relating to
CRL’s capabilities, provided that no such use may violate the provisions set forth above in Paragraph 7, Confidentiality. 
  
 17. Reporting. At CLIENT’s request, CRL will promptly provide CLIENT with a copy of all records relating to CRL’s provision of Services or Out of Scope
Services under this Agreement. If any regulatory authority conducts or gives notice to CRL of its intent to conduct an inspection of CRL or any study site for which Services or Out of Scope Services are being provided or to take any other action
with respect to the Services or Out of Scope Services provided under this Agreement, CRL shall promptly notify CLIENT of this action or proposed action and shall allow CLIENT to participate in any proceedings related thereto. 
  
 18. Notification. Any notices that either party may be required or shall desire to
give hereunder shall be written and shall be deemed to have been given on the earlier of: (a) when received personally by the party’s Authorized Representative, or (b) when received at the party’s regular business address. Notice may be
given by any means, such as by mail, overnight courier, facsimile/telecopier, , personal delivery, etc. All notices shall be sent to the Authorized Representative of the party to whom notice is to be given. The Authorized Representative of each
party shall be as indicated in the signature line below together with such other representatives of such party as may be appointed by the Authorized Representative by notice in writing to the other party. 
  
 19. Waiver. No waiver of any right or remedy with respect to any occurrence or event
shall be valid unless it is in writing and executed by the waiving party. Furthermore no such valid waiver shall be deemed a waiver of such right or remedy with respect to such occurrence or event on a continuing basis or in the future unless the
waiver states that it is intended to apply continuously or to future events. A waiver shall not excuse a subsequent breach of the same term, unless the waiver so states. 
  
 20. Severability. If any provisions of this Agreement are determined to be invalid or unenforceable, those provisions shall be
reformed to the extent necessary to comply with law and the parties’ intent, or struck if necessary, and the validity and effect of the other provisions of this Agreement shall not be affected. 
  

 Page 9 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 21. Dispute Resolution. 
  
 21.1 (a) Arbitration. Any controversy, claim or dispute arising out of or in connection with or relating to this
Agreement, the breach or alleged breach thereof, or the termination or invalidity thereof, shall be resolved by binding arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”) (the
“Rules”) in effect as of the day the arbitration demand is filed, and the procedures set forth below. In the event of any inconsistency between the Rules and the procedures set forth below, the procedures set forth below shall control.
Notwithstanding the above, each party shall have the right to seek provisional equitable remedies (e.g., temporary restraining orders and/or preliminary or permanent injunctions) in a court of competent jurisdiction to protect its intellectual
property rights and/or confidential information. 
  
 (b)
Governing Law. The arbitration shall be governed in all respects by the laws of the State of Delaware, USA (the “Selected Law”) without regard to its conflicts of law provisions. Any inconsistency between the Selected Law and the
Rules shall resolved in favor of the Selected Law, subject to the terms in this Agreement. 
  
 (c) Location and Language. The location of the arbitration shall be in the City of Wilmington, Delaware, USA. The Arbitration shall be conducted in English and any findings and/or decisions shall be rendered in
English. 
  
 (d) Selection of Arbitrator. The arbitration
shall be conducted by one arbitrator who is independent and disinterested with respect to the parties, this Agreement, and the outcome of the arbitration. If the parties are not able to mutually agree on an arbitrator, then an arbitrator shall be
appointed as provided in the Rules. The arbitrator will be selected with consideration given to his or her experience with disputes of the nature being submitted (e.g., the nature of the claim and the technology involved) and will, if possible, be a
former judge. It is the intent of the parties that the arbitrator be selected within thirty (30) calendar days after the date the dispute is submitted by a party to AAA. 
  
 (e) Discovery. The parties shall have discovery as provided under the Federal Rules of Civil Procedure in existence
at that time as applied in the local federal district court. The arbitrator shall decide any disputes and shall control the process concerning these pre-hearing discovery matters. Pursuant to the Rules, the parties may subpoena witnesses and
documents for presentation at the hearing. 
  
 (f) Case
Management. Prompt resolution of any dispute is important to both parties; and the parties agree that the arbitration of any dispute shall be conducted expeditiously. The arbitrator is instructed and directed to assume case management initiative
and control over the arbitration process (including scheduling of events, pre-hearing discovery and activities, and the conduct of the hearing), in order to complete the arbitration as expeditiously as is reasonably practical for obtaining a just
resolution of the dispute. 
  
 (g) Remedies. The arbitrator
shall follow and apply the applicable law. The arbitrator shall grant such legal or equitable remedies and relief in compliance with applicable law that the arbitrator deem just and equitable, but only to the extent that such remedies or relief
could be granted by a state or federal court and as otherwise limited by the terms in this Agreement. No punitive damages may be awarded by the arbitrator. No court action may be maintained seeking punitive damages. 
  
 (h) Expenses. The expenses of the arbitration, including the
arbitrator’s fees, expert witness fees, and attorney’s fees, may be awarded to the prevailing party, in the discretion of the arbitrator, or may be apportioned between the parties in any manner deemed appropriate by the arbitrator. Unless
and until the arbitrator decides that one party is to pay for all (or a share) of such expenses, both parties shall share equally in the payment of the arbitrator’s fees as and when billed by the arbitrator. 
  
 (i) Confidentiality. Except as set forth below, the parties shall keep
confidential the fact of the arbitration, the dispute being arbitrated, and the decision of the arbitrator. Notwithstanding the foregoing, the parties may disclose information about the arbitration to persons who have a need to know, such as
directors, trustees, management employees, witnesses, experts, investors, attorneys, lenders, insurers, and others who may be directly affected. Additionally, if a party has stock which is publicly traded, the party may make such disclosures as are
required by applicable securities laws. Further, if a party is expressly asked by a third party about the dispute or the arbitration, the party may disclose and acknowledge in general and limited terms that there is a dispute with the other party
which is being (or has been) arbitrated. 
  

 Page 10 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 (j) Enforcement. Any arbitration award may be enforced by any court of competent jurisdiction,
and, notwithstanding (i) above, either party may disclose such information to the court as is reasonably necessary to enforce the award. 
  
 21.2 Notwithstanding the foregoing, either party may bring an injunction proceeding before a court of equity in the event that damages for a breach are
not likely to be an adequate remedy, such proceeding to be brought only in a judicial district that includes Durham County, North Carolina, and the parties hereby consent to the jurisdiction of such court. 
  
 22. Survival. The rights and obligations set forth in Paragraphs 4, 5, 7, 8, 9, 10,
11, 13, 16, 17, 21 and 22 shall survive termination or expiration of this Agreement. 
  
 23. Client Obligations. 
  
 23.1 CLIENT
hereby agrees to undertake the following obligations with respect to the performance of this Agreement. Any failure by CLIENT to perform any of the specified obligations shall be a material breach of this Agreement. 
  
 23.2 CLIENT shall deliver all information and materials required for the
performance of the Services or Out of Scope Services in accordance with the mutually agreed upon timelines established by CRL and CLIENT. 
  
 23.3 CLIENT shall immediately apprise CRL of any safety concerns or serious adverse events related to the drug, compounds and/or materials that are the
subject of the Services or Out of Scope Services. 
  
 23.4 CLIENT
shall not take any actions or participate in any activities intended to or that can be reasonably expected to disrupt or interfere with any of the obligations transferred to CRL pursuant to this Agreement. CLIENT agrees to participate in activities
related to such transferred obligations only in the manner specified by CRL. 
  
 23.5 CLIENT hereby agrees that all CLIENT employees and agents who interact with CRL personnel in the provision of Services or Out of Scope Services will conduct themselves in a professional manner consistent with the
standards in the industry and will refrain from the use of foul or abusive language when communicating with CRL personnel. 
  
 24. Audit. CRL agrees that it will, on no less than two (2) weeks notice, during regular business hours, permit a regulatory auditor selected by CLIENT (qualified
by education, training, and experience) to have access to CRL’s records pertaining to the Services provided pursuant to this Agreement, for the purpose of auditing and verifying the Services rendered pursuant to this Agreement. Such auditor
shall report to CLIENT only his or her conclusions from the audit. The cost of any such audit shall be borne by CLIENT, and, if the audit exceeds three (3) days in duration, CLIENT shall be obligated to reimburse CRL on a time-and-materials basis at
rates that shall be agreed to by CLIENT and CRL, for the CRL personnel assigned to supervise such audit and any other CRL personnel who are required to participate in such audit. Only one such audit shall be made in any one (1) calendar year. Any
information obtained from an audit shall be kept confidential. 
  
 25.
Assignment. This Agreement may not be assigned by either party without the prior written consent of the other party, which consent shall not be unreasonably withheld; provided, however, that either party may assign this Agreement without the
prior written consent of the other party in connection with a merger or the sale of all or substantially all of the assigning party’s assets or stock; and, provided further that such assignment shall be solely to the acquirer or purchaser of
the assigning party. 
  
 26. Freedom to Contract. Subject to the provisions
in Paragraph 1 and 2 hereof, this Agreement does not require CLIENT to use CRL for any specific work, and CLIENT is free to retain other businesses to perform the same or similar services as offered by CRL hereunder. This Agreement does not require
CRL to provide any Services or Out of Scope Services to CLIENT, and CRL is free to reject any request for a Work Package in which CRL does not wish to participate. CRL shall not perform any services for Adenosine Therapeutics, Inc. during or within
two years after the termination date of this Agreement. 
  
 27. Entire
Agreement. Exhibits A, B-1 and B-2 and C to this Agreement, any subsequently attached Work Packages, and the protocols for any applicable clinical trials are incorporated into and made a part of this Agreement. This
Agreement, including the Exhibits (and documents referenced in the Exhibits), Work Packages, and clinical trial protocols, embodies the entire agreement between CRL and CLIENT relating to the subject matter hereof, and hereby amends, restates, and
replaces the Prior Agreement in its 

  

 Page 11 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 
entirety. The parties shall not be bound by or liable for any statement, writing, representation, promise, inducement, or understanding not set forth above
or in a Work Package or an Exhibit hereto. No changes, modifications, or amendments of any term shall be valid unless agreed upon by the parties in writing. Any agreement between the parties purporting to amend a term or condition of this Agreement
shall, to be effective, specifically identify that term or condition’s paragraph number, and shall include the parties’ specific intent to amend that term or condition. CRL’s entry into this Agreement is expressly made conditional on
CLIENT’s assent to the terms set forth herein, and not those in any purchase order, confirmation, or similar form that may be attached by CLIENT, and CLIENT agrees that any additional or different terms in any such form, whether attached hereto
or to any of the Exhibits, now or in the future, are void even if the form indicates it shall control. 
  
 28. Execution of Agreement. The terms and conditions contained herein shall be void if this Agreement is not fully executed and returned to CRL within thirty (30) days following the date first written
above. 
  
 In witness thereof, the parties have executed this Amended
and Restated Strategic Master Services Agreement as of the day and the year first above written. 
  

									
	 CRL: Cato Research Ltd.
 200 Westpark
Corporate Center
 4364 South Alston Avenue
 Durham, North
Carolina 27713-2280
	 	 	 	 CLIENT: Duska Scientific Co.
 Two Bala Plaza, Suite 300
 Bala Cynwyd, Pennsylvania 19004

					
	By:	 	 	 	 	 	By:	 	 
					
	 Title:  
	 	 	 	 	 	 Title:  
	 	 

  

 Page 12 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 EXHIBIT A 
  
 WORK ORDER REQUEST 
  
 Cato Research Ltd. 
  
 Contact Information:    (Exhibit to be completed by CRL personnel) 
  

					
	 CLIENT
 Contact
Name:                                       
                  
	 	 	  	 CRL Contact:

                                       
                                        
  

	 Date Work
 Requested:                                     
                            
	 	 	  	 

  
 Details of Service: (Exhibit to be
completed by CRL Personnel) 
 Description of Service: 
  
  
  
  
  
  
 Specifications: 
  
  
  
  
  
  

					
	Fees: $	 	 Payment Terms:        To Be Determined
	  	 
		
	 Estimated Start
 Date:
                                        
                
	 	Estimated Completion Date: ____________________________

  
 We have reviewed the specifications
and fees and agree to proceed with the work described above. 
  
 CLIENT Signature: _______________________________________________________        Date: ________________________ 
  
 Additional Comment: ______________________________________________________________________________________ 
  
 Fax (or mail) the signed form to your CRL contact identified
above. If you have any questions call your CRL Contact. 
  

 Page 13 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 EXHIBIT B-1 
  
 Special Compensation Arrangement for up to $1,250.000 of Phase 2 ATPaceTM Study Services 
  
 1. Background 
  
 1.1 CLIENT and CRL contemplate that CRL will perform up to $1,250,000 of Phase 2 ATPaceTM Study Services as set forth in the Description of Services. CRL will provide
Phase 2 ATPaceTM Study Services to CLIENT in
accordance with the fee amounts set forth in the Description of Services for the Agreement and pursuant to the mutually agreed-upon specifications, instructions, or guidelines described in the Description of Services. CRL will have no
obligation to perform any of the Phase 2 ATPaceTM
Study Services until CLIENT has completed a Qualified Financing (as defined in Section 2.3 below). 
  
 1.2 This Phase 2 ATPaceTM Study Special Compensation Arrangement is intended to establish the ratio of cash and securities payments by CLIENT to Cato Holding Company for up to
$1,250,000 of CRL Phase 2 ATPaceTM Study Services
rendered under the Agreement. 
  
 1.3 Capitalized terms not
defined herein have the meanings ascribed to them in the Agreement. 
  
 2.
Special Compensation Arrangement for Phase 2 ATPaceTM Study Services 
  
 2.1 The
special compensation arrangement for the Phase 2 ATPaceTM Study Services performed pursuant to the Agreement and specifically set forth in this Phase 2 ATPaceTM Study Special Compensation Arrangement shall apply only to the up to $1,250,000 of compensation payable by CLIENT to CRL (excluding CLIENT’s
payments to CRL for out-of-pocket expenses as set forth in Exhibit C to this Agreement) for Phase 2 ATPaceTM Study Services rendered under the Agreement. Unless and until the Agreement and this Phase 2 ATPaceTM Study Special Compensation Arrangement are amended by the Parties, all compensation payable by CLIENT to CRL in excess
of $1,250,000 for Phase 2 ATPaceTM Study Services
rendered under the Agreement shall be paid 100% in cash pursuant to the standard arrangements set forth in the Agreement and in accordance with the rates to be agreed to by CLIENT and CRL.  
  
 2.2 CLIENT shall pay and reimburse to CRL, in cash, on a monthly basis, all
of CRL’s out of pocket expenses as specified in Exhibit C to the Agreement, and said amounts shall not be subject to this Phase 2 ATPaceTM Study Special Compensation Arrangement. 
  
 2.3 A “Qualified Financing” shall be the first financing by CLIENT of its equity securities completed by CLIENT after January 1, 2004 in which
CLIENT receives net offering proceeds of at least $2,000,000 from one or more investors. The equity securities sold in the Qualified Financing are referred to herein as the “Financing Securities.” As a retainer fee and not later than the
date upon which CRL commences Phase 2 ATPaceTM
Study Services under this Agreement, CLIENT shall issue to and hold in escrow on behalf of Cato Holding Company (as the designee of CRL) $500,000 of Financing Securities (valued at the same price at which the Financing Securities are sold in the
Qualified Financing). The aggregate value of these escrowed securities (the “Retainer Shares”) shall be deemed to equal for purposes of the Agreement $500,000 (40% of $1,250,000) at the time of issuance. The issuance of the Financing
Securities will be made pursuant to a securities purchase or subscription agreement (the “Securities Purchase Agreement”) acceptable to CLIENT and Cato Holding Company, which agreement will contain, among other things, appropriate
representations and warranties of CLIENT and Cato Holding Company, covenants of CLIENT reflecting the provisions set forth in the Agreement, and appropriate conditions to issuance and acceptance of the Financing Securities by Cato Holding Company,
which will include, among other things, qualification or exemption of the issuance of the securities to Cato Holding Company under applicable Blue Sky laws. All of the Retainer Shares also shall be entitled to the special rights, preferences and
privileges, if any, of the Financing Securities issued to investors in the Qualified Financing. As set forth below, CRL shall earn a portion of the Retainer Shares periodically as CRL renders Phase 2 ATPaceTM Study Services to CLIENT under the Agreement. 
  
 2.4 On a monthly basis during the term of the Agreement, CRL shall prepare
and submit to CLIENT a written invoice for Services rendered to CLIENT during the period covered by the invoice in accordance with the terms of the Agreement . Such invoices shall be payable by CLIENT as follows: 60% of the invoiced amount shall be
payable in cash (the “Cash Component”) and 40% of the invoiced amount shall be payable in the form of a portion of the Retainer Shares (the “Stock Component”). The number of shares constituting the Stock Component earned by CRL
each month shall be determined by 

  

 Page 14 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 
dividing the invoiced dollar amount of the Stock Component (i.e., 40% of the amount due for Services rendered in the period covered by the invoice) by the
price at which the Financing Securities were sold in the Qualified Financing. For example, if the Financing Securities are units, each consisting of 1 share of common stock and a warrant to purchase one share of common stock (“Units”) sold
at $1 per Unit in the Qualified Financing and if the total invoiced amount were $100,000, such amount would be payable by CLIENT as follows: $60,000 in cash and 40,000 Units as the Retainer Shares ($40,000= $1 per Unit). Each portion of the Retainer
Shares so earned from time to time by CRL for Phase 2 ATPaceTM Study Services rendered shall be referred to as “Earned Retainer Shares”; and the remaining portion of the Retainer Shares which are not yet earned by CRL shall be referred to as “Unearned Retainer
Shares.” 
  
 2.5 In the event that the Agreement is
terminated before CRL performs a total of $1,250,000 of Phase 2 ATPaceTM Study Services for CLIENT (calculated from the effective date of the Agreement to the effective date of the termination), as soon as practicable following the date of CRL’s final invoice for ordinary wind down
Phase 2 ATPaceTM Study Services permitted under the
Agreement after the effective date of the termination; CRL shall return to CLIENT any and all Unearned Retainer Shares for cancellation by CLIENT without any further compensation to CRL. 
  
 2.6 In addition to the foregoing compensation, at the time CRL commences the Phase 2 ATPaceTM Study Services under the Agreement, CLIENT shall issue to Cato Holding
Company a warrant to purchase 33,000 shares of CLIENT’s Common Stock at a purchase price of $3.125 per share (the “Warrant”). The Warrant shall be transferable by Cato Holding Company to its employees, provided that each such
transferee is an “accredited investor” as defined in Regulation D under the Securities Act of 1933, as amended, and shall be exercisable at any time up to the first to occur of 1) five (5) years following the date of the Agreement, 2) one
(1) day prior to any change in control of CLIENT, or 3) the date of closing of CLIENT’s initial public offering; so long as CRL is given at least thirty (30) days’ prior written notice as to events 2 or 3 above. The Warrant shall also
include provisions for cashless exercise thereof and other customary provisions. 
  

 Page 15 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 EXHIBIT B-2 
  
 Special Compensation Arrangement for Phase 3 ATPaceTM Study Services 
  
 1. Background 
  
 1.1 CLIENT and CRL contemplate that CRL may perform Phase 3 ATPaceTM Study Services as may be set forth in the Description of Services for the Agreement. CRL will provide Phase 3
ATPaceTM Study Services, if any, to CLIENT in
accordance with the fee amounts that will be agreed to by CLIENT and CRL and set forth in the Description of Services for the Agreement. 
  
 1.2 This Phase 3 ATPaceTM Study Special Compensation Arrangement is intended to establish the ratio of cash and securities payments by CLIENT to Cato Holding Company for up to
the specified amount of CRL Phase 3 ATPaceTM Study
Services rendered under the Agreement, if any, and set forth in the Description of Services (the “Specified Amount”) in the event CLIENT elects prior to the commencement of such services, at its sole discretion, to pay for a portion of the
Phase 3 ATPaceTM Study Services under this
Agreement with equity securities of CLIENT. CRL shall have no obligation to perform any of the Phase 3 ATPaceTM Study Services for payment in other than cash as provided in Section 2 of this Exhibit B-2 unless and until CLIENT has generated total cumulative net proceeds of at least $5,000,000 from
one or more of the following sources: the Qualified Financing, any subsequent financing, upon the exercise of its stock options or warrants, license fees or other strategic alliance payments or research grant payments from the NIH or any other
governmental agency or private institution. 
  
 1.3 Capitalized
terms not defined herein have the meanings ascribed to them in the Agreement. 
  
 2. Special Compensation Arrangement for Phase 3 ATPaceTM Study Services 
  
 2.1 The
special compensation arrangement for Services performed pursuant to the Agreement and specifically set forth in this Phase 3 ATPaceTM Study Special Compensation Arrangement shall apply only up to the Specified Amount of compensation payable by CLIENT to CRL (excluding CLIENT’s
payments to CRL for out-of-pocket expenses as set forth in Exhibit C to this Agreement) for Phase 3 ATPaceTM Study Services rendered under the Agreement, if any. Unless and until the Agreement and this Phase 3 ATPaceTM Study Special Compensation Arrangement are amended by the Parties, all compensation payable by CLIENT to CRL in excess
of the Specified Amount for Phase 3 ATPaceTM Study
Services rendered under the Agreement, if any, shall be paid 100% in cash pursuant to the standard arrangements set forth in the Agreement and in accordance with the rates to be agreed to by CLIENT and CRL. 
  
 2.2 CLIENT shall pay and reimburse to CRL, in cash, on a monthly basis, all
of CRL’s out of pocket expenses as specified in Exhibit C to the Agreement, and said amounts shall not be subject to this Phase 3 ATPaceTM Study Special Compensation Arrangement. 
  
 2.3 As a retainer fee and not later than the date upon which CRL commences providing Phase 3 ATPaceTM Study Services under this Agreement, if any, CLIENT shall issue to and hold in escrow
on behalf of Cato Holding Company (as the designee of CRL) an amount of Financing Securities (as defined in Exhibit B-1 and valued at the same price at which the Financing Securities were sold in the Qualified Financing) equal to the
Specified Amount x 32.1%. The aggregate value of these escrowed securities (the “Retainer Shares”) shall be deemed to equal for purposes of the Agreement (32.1% of the Specified Amount) at the time of issuance. 
  
 The issuance of the Financing Securities will be made pursuant to a
securities purchase agreement acceptable to CLIENT and Cato Holding Company, which agreement will contain, among other things, appropriate representations and warranties of CLIENT and Cato Holding Company, covenants of CLIENT reflecting the
provisions set forth in this Agreement, and appropriate conditions to issuance and acceptance of the Financing Securities by Cato Holding Company, which will include, among other things, qualification or exemption of the issuance of the securities
to Cato Holding Company under applicable Blue Sky laws. The representations and warranties and covenants of CLIENT will be substantially the same as those set forth in the Securities Purchase Agreement to be entered into by CLIENT and CRL in
connection with the issuance of CLIENT’s securities to CRL pursuant to Exhibit B-1 to the Agreement. 
  

 Page 16 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 As set forth below, CRL shall earn a portion of the Retainer Shares periodically as CRL renders Phase
3 ATPaceTM Study Services to CLIENT under the
Agreement. 
  
 2.4 On a monthly basis during the term of the
Agreement, CRL shall prepare and submit to CLIENT a written invoice for Services rendered to CLIENT during the period covered by the invoice in accordance with the terms of the Agreement. Subject to Section 2.3 above, such invoices shall be payable
by CLIENT as follows: sixty-seven and nine-tenths (67.9%) of the invoiced amount shall be payable in cash (the “Cash Component”) and thirty-two and one-tenth percent (32.1%) of the invoiced amount shall be payable in the form of a portion
of the Retainer Shares (the “Stock Component”). The amount constituting the Stock Component earned by CRL each month shall be determined by multiplying the invoiced dollar amount by thirty-two and one-tenth percent (32.1%) and the number
of shares constituting the Stock Component earned by CRL each month shall be determined by dividing the invoiced dollar amount of the Stock Component (i.e., 32.1% of the amount due for Services rendered in the period covered by the invoice) by the
price at which the Financing Securities were sold in the Qualified Financing. For example, if the Financing Securities are units, each consisting of 1 share of common stock and a warrant to purchase one share of common stock (“Units”) sold
at $1 per Unit in the Qualified Financing and if the total invoiced amount were $100,000, such amount would be payable by CLIENT as follows: $67,900 in cash and 32,100 Units as the Retainer Shares. Each portion of the Shares so earned from time to
time by CRL for Phase 3 ATPaceTM Study Services
rendered shall be referred to as “Earned Retainer Shares”; and the remaining portion of the Retainer Shares which are not yet earned by CRL shall be referred to as “Unearned Retainer Shares” 
  
 2.5 In the event that the Agreement is terminated before CRL performs the
Specified Amount of Phase 3 ATPaceTM Study Services
for CLIENT (calculated from the effective date of the Agreement to the effective date of the termination), as soon as practicable following the date of CRL’s final invoice for ordinary wind down Phase 3 ATPaceTM Study Services permitted under the Agreement after the effective date of the
termination, CRL shall return to CLIENT for cancellation by CLIENT any and all Unearned Retainer Shares without any further compensation to CRL. 
  

 Page 17 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 EXHIBIT C 
  
 EXPENSES 
  
 CLIENT shall reimburse CRL for actual, reasonable and necessary out-of-pocket third-party expenses incurred by CRL on CLIENT’s behalf in connection
with CRL’s performance of the Services and any Out of Scope Services, including, among other things, shipping, teleconference, copying and transportation, lodging, and subsistence expenses for visits to sites away from CRL’s office,
provided that CLIENT has authorized such visits. With respect to travel expenses, this reimbursement shall be limited by the following: 
  

	 	(a)	Airline travel shall be via commercial airline at no more than full coach fare or business class for transoceanic travel; 

  

	 	(b)	Local travel to sites other than CRL’s office shall be by personal car at a rate not to exceed the prevailing maximum reimbursement rate allowed by the federal government; and

  

	 	(c)	Local travel at locations remote from CRL’s office shall be by rental car, or taxi, whichever is more cost efficient. 

  

 Page 18 of 19 

			
	 CONFIDENTIAL
	  	 Duska Scientific Co./Cato Research Ltd.
 Phase 2/3 Program Master Services Agreement

  

 February 10, 2004 
  
 CATO Research Ltd. 
 200 Westpark Corporate
Center 
 4364 South Alston Avenue 
 Durham, North Carolina
27713-2280 
  
 Gentlemen: 
  
 This will confirm that commencement of the Phase 2 ATPaceTM Study and the Services related thereto under the Amended and Restated Strategic Master Services Agreement (MSA), effective as
of February 10, 2004 between Duska Scientific Co. (CLIENT) and Cato Research Ltd. (CRL) is subject to CLIENT receiving at least $2 million of net proceeds from its pending equity offering, and CLIENT shall have no obligation or liability to CRL if
it is unable to authorize commencement of any Phase 2 ATPace Study Services under the MSA due to its failure to raise at least $2 million of net proceeds so as to be able to conduct the Phase 2 ATPace Study in its entirety. Similarly, CRL shall have
no obligation or liability to CLIENT to perform any of the Phase 2 ATPace Study Services if CLIENT fails to raise at least $2 million of net proceeds to conduct the Phase 2 ATPace Study so as to be able to conduct this study in its entirety.
Commencement of the Phase 3 ATPaceTM Study and the Services related thereto is subject to CLIENT receiving a
cumulative total of at least $5 million of funding in the form of net proceeds from one or more of the following sources: financings (including CLIENT’s currently proposed financing), option or warrant exercises, license fees or other strategic
alliance payments or research grants from the NIH or any other governmental agency or private institution so as to be able to finance such study, and CLIENT shall have no obligation or liability to CRL if it is unable to authorize commencement of
any Phase 3 ATPace Study Services under the MSA due to its failure to raise at least the $5 million of funding so as to be able to conduct the Phase 3 ATPace Study in its entirety. Similarly, CRL shall have no obligation or liability to CLIENT to
perform any of the Phase 3 ATPace Study Services if CLIENT fails to raise at least the $5 million (including CLIENT’s currently proposed financing) of funding so as to be able to conduct the ATPace Phase 3 Study in its entirety. 
  
 We would appreciate your confirming your agreement with the above by signing
in the space provided below. 
  

			
	 Very truly yours,

	
	 DUSKA SCIENTIFIC CO.

		
	By:	 	 
	 	 	Dr. Amir Pelleg

  
 Agreed to and Accepted as of
this 10th day of February 2004: 
  

			
	 CATO RESEARCH LTD.

		
	By:	 	 
	 	 	 
	 	 	 Title

  

 Page 19 of 19Agreement between Duska Scientific Co. and CooperSurgical, Inc.

 EXHIBIT 10.4 
  
 Execution Copy 
  
 COOPERSURGICAL, INC. 
  
 April 30, 2004 
  
 CONFIDENTIAL 
  
 Duska Scientific Co. 

Two Bala Plaza, Suite 300 
 Bala Cynwyd, PA 19004 
 Attention: Dr. Amir Pelleg, President 
  

	 	Re:	Exclusivity Letter Relating to Evaluation of Technology Transaction 

  
 Gentlemen: 
  
 CooperSurgical, Inc., a Delaware corporation (“Cooper”), and Duska Scientific Co., a Delaware corporation (“Duska”), have been engaged in discussions regarding a possible transaction
(a “Proposed Transaction”) between Cooper (or an affiliate of Cooper) and Duska concerning the possible license by Duska of the Technology to Cooper. This Letter Agreement (the “Agreement”) sets forth the agreements
of Cooper and Duska with respect to Cooper’s evaluation of the Technology and the basis, including the non-binding terms set forth on Exhibit 2 attached hereto, on which Cooper and Duska contemplate negotiation of a Proposed Transaction.

  
 This Agreement is intended to be a binding agreement of the
parties hereto. HOWEVER, THIS AGREEMENT DOES NOT CONSTITUTE A BINDING AGREEMENT WITH RESPECT TO ANY PROPOSED TRANSACTION, WHICH SHALL BE SUBJECT TO THE NEGOTIATION AND EXECUTION OF DEFINITIVE DOCUMENTS. 
  
 Capitalized terms used but not otherwise defined in this Agreement have the
meanings given to them on Exhibit 1 attached hereto. 
  

 1 

 In consideration of the substantial time and expense to be incurred by Cooper in conducting due diligence
regarding and evaluating the Technology and the Proof of Principle Study (as defined below), the results of which will be available to Duska, and the provision by Cooper to Duska of Cooper’s United States Food & Drug Administration
(“FDA”) approved in-vitro culture media and sperm separation media (collectively, the “Media”), Cooper and Duska agree as follows: 
  
 1. Exclusive Dealings. 
  
 (a) During the Exclusivity Period (as defined below), Duska, its affiliates, their respective officers and directors and all other Persons
acting on their behalf, shall not solicit or conduct any discussions, enter into any negotiations, enter into any agreements, understandings or transactions or provide any information to any Person, other than Cooper and its representatives, with
respect to or relating to any sale, lease, license, pledge, charge, hypothecation or other disposition or encumbrance of all or any material aspect of the Technology (a “Technology Transaction”). If Duska, its affiliates or their
respective officers, directors or representatives, receive any oral or written offer or proposal to engage in discussions relating to a Technology Transaction, then Duska shall immediately notify Cooper of the identity of the Person making, and the
specific terms of, any such offer or proposal. Duska represents to Cooper that it is not bound to negotiate any Technology Transaction with any other Person and that the execution by Duska of this Agreement does not and will not violate any
agreement to which it is bound or to which the assets of Duska are subject. Notwithstanding the foregoing, any actual or contemplated merger or consolidation of Duska or any sale of all or substantially all of the assets of Duska shall not be deemed
a Technology Transaction as long as Cooper’s rights, and the performance of Duska’s duties and obligations by Duska or its successor under this Agreement, are not adversely affected in any way by such transaction. 
  
 (b) The parties recognize and acknowledge that a breach by
Duska of the provisions of this Section 1 may cause irreparable and material loss and damage to Cooper which cannot be adequately remedied at law and that, accordingly, in addition to, and riot in lieu of, any damages or other remedy to which Cooper
may be entitled, the issuance of an injunction or other equitable remedy (without the requirement that a bond or other security be posted) is an appropriate remedy for Cooper for any breach of the obligations set forth in this Section 1. 

 
 (c) “Exclusivity Period” means the
period beginning on the date hereof and ending sixty (60) days after the Proof of Principle Study is complete (as determined in accordance with Section 2 of this Agreement). If at the end of the initial Exclusivity Period the parties have not
executed one or more definitive agreements for the Proposed Transaction and neither party has by written notice to the other party terminated any negotiations between them, either party may elect to extend the Exclusivity Period for an additional
sixty (60) day period. Such election shall be made by written notice to the other party within five calendar days prior to the end of the initial Exclusivity Period. 
  
 2. Proof of Principle Study. 
  
 (a) To assist Cooper in its evaluation of the Technology, Duska will use the Technology in the Media to
conduct, and enable others to conduct on its behalf, the Proof of Principle Study. In this Agreement, the “Proof of Principle Study” or the “Study” means preclinical studies required by the FDA to prove the
effectiveness and safety of the Technology used in the Media to enhance the acrosome reaction of human and animal sperm in-vitro (such enhancement being called, the “Applications”). Duska will design the Proof of Principle Study and
provide Cooper with a written description of the Study’s objectives, the means to be used to achieve those objectives and an estimated timetable to carry out and complete the Study and to prepare a final Study report (the “Final Study
Report”) reflecting the results of the Study. The 

  

 2 

 
Proof of Principle Study shall be deemed complete (for purposes of determining the date the Exclusivity Period ends) upon completion of the Study and
delivery to Cooper and Duska of the Final Study Report. In the event that Duska desires to publish the Final Study Report in a professional journal, it shall deliver to Cooper a copy of such report in the form that Duska wishes to publish so as to
enable Cooper for a period of at least thirty (30) days to review and comment on such report. Duska shall make changes in such report as may be reasonably requested by Cooper after Cooper’s review thereof. Cooper will abide by any scientific
data publication clause contained in Duska’s agreements with the academic institutions contracted by Duska to conduct the Study, provided that Duska provides Cooper with a copy of any such clause and any policies related thereto, and provided
further that Cooper shall not have any other obligation under any agreement between Duska and such academic institutions. 
  
 (b) Upon completion of the Study and the processing of the data thereof, Duska will submit an Investigational New Drug Application
(“IND”) to the FDA. In conducting the Study, Duska will at its own expense (i) formulate the Product so that it is adapted to function effectively in the Media, (ii) conduct the Study with professionals engaged in the business of
providing assisted reproduction technology, (iii) conduct the Study in accordance with standards of good clinical practice and under protocols that carry prior FDA approval and in a manner to support application to the FDA for marketing approval of
the Product and (iv) complete the Study as provided above. In conducting the Proof of Principle Study, Duska shall, at its expense, exercise its commercially reasonable efforts to make such changes and adjustments to the Product and its formulation
in the Media as may be reasonably required based on the recommendations made by Cooper and the clinical investigators conducting the clinical part of the Study. Duska shall have the right to evaluate the Media, and Cooper shall, at its expense,
exercise its commercially reasonable efforts to make such changes and adjustments to the Media as may be reasonably required based on the recommendations made by Duska in connection with the Product and its formulation. 
  
 (c) Cooper will provide, at its expense, to Duska sufficient
quantities of the Media for the Study and technical assistance as may be reasonably requested by Duska in connection with the entire Study or as may be determined by Cooper to be required to support the use of the Media in the Study. 
  
 (d) Notwithstanding any other provision in this Agreement,
all protectable intellectual property derived from the Study shall vest in and be the exclusive property of Duska, provided that such intellectual property relating solely to the Media shall vest in and be the exclusive property of Cooper.

  
 3. Evaluation by Cooper. During the Exclusivity Period,
while Duska is conducting the Proof of Principle Study, Cooper intends to evaluate (i) the applications of the Technology for use in the Applications and (ii) Duska’s patent protection for the Technology. 
  
 4. Information and Access. 
  
 (a) From and after the date hereof and until the expiration
of the Exclusivity Period, Duska shall afford and shall cause its counsel to afford to the officers, accountants, counsel and other representatives of Cooper access to the properties, books, records and 

  

 3 

 
personnel of Duska relating to the Technology, including, without limitation, all information and materials related to any patents providing protection for
the Technology and all information relating to compliance of the Study with FDA procedures and communications to and from the FDA relating to the Study and possible FDA approval of the Product. Cooper and Duska shall each provide the other with
access on request to the results from time to time of the Proof of Principle Study, and such results shall be deemed confidential information of each such party under the Confidentiality Agreement referenced in Section 8 below. Duska shall provide
monthly to Cooper the most recent information concerning and derived from the Study (including information relating to the FDA). Notwithstanding the foregoing or the terms of the Confidentiality Agreement, in the event Cooper and Duska have not
entered into a Proposed Transaction prior to the end of the Exclusivity Period, then Duska may thereafter share the results of the Proof of Principle Study with third parties, provided that no such results or any other materials or information
related to the Proof of Principle Study are attributed to Cooper or use Cooper’s name in any way without Cooper’s prior written approval in each instance. Cooper shall also provide Duska access to the results of any written market research
and marketing plans of Cooper regarding the Technology after they become available to or are developed by Cooper. Duska and Cooper are each permitted to disclose the existence and general terms of this Agreement to the extent required by law.

  
 (b) Duska shall provide Cooper with
reasonable advance notice of the dates when and the locations where Duska is performing the Study. At the request of Cooper, Duska will provide Cooper with reasonable access to the clinical investigators and other professionals participating in the
Study so that Cooper may contact those professionals to discuss the Study and the evaluation of the Technology. 
  
 5. Termination by Duska or Cooper. 
  
 (a) Cooper may at any time during the Exclusivity Period determine, in its discretion, to terminate its evaluation of the Technology and
its participation in the Proof of Principle Study. Cooper will notify Duska of such a determination promptly after it is made. In the event that Cooper and Duska do not enter into a Proposed Transaction for any reason and Duska has not terminated
this Agreement under the first sentence of Section 5(b) or Cooper has not terminated this Agreement under Section 5(c), Cooper shall from time to time upon Duska’ s request provide, to the extent available, Media to Duska for use with the
Product or the Technology. Cooper shall provide such Media for a period of three years starting from the earlier of (i) the date on which Cooper terminates its evaluation of the Technology and its participation in the Study pursuant to this Section
5(a) or (ii) the date on which the Exclusivity Period ends. For each request by Duska for Media, the price of the Media shall be the per unit price generally charged by Cooper to third parties at the time of such request. 
  
 (b) Duska may at any time during the Exclusivity Period
terminate this Agreement without liability to Cooper (other than liability under Section 5(d)) if Duska in good faith determines, after review of preliminary data produced by the Study, that the Study will not for any reason generate safety and
efficacy data that could support a NDA filing for a commercially viable Product. Duska shall provide Cooper with a copy of the data and any related analysis used by Duska in making such a determination. Duska may also terminate this Agreement upon a
material breach by Cooper of its obligations under this Agreement, if such 

  

 4 

 
breach remains uncured for more than twenty (20) days following written notice of such breach by Duska. Duska will promptly notify Cooper of any such
termination. 
  
 (c) Cooper may terminate this
Agreement upon a material breach by Duska of its obligations under this Agreement, if such breach remains uncured for more than twenty (20) days following written notice of such breach by Cooper. Cooper will promptly notify Duska of any such
termination. 
  
 (d) The liability of any party
arising from any breach of this Agreement occuring prior to the termination of this Agreement shall survive the termination of this Agreement. 
  
 6. Governing Law. All questions concerning the construction, interpretation and validity of this Agreement shall be governed by and construed and
enforced in accordance with the domestic laws of the State of New York, without giving effect to any choice or conflict of law provision or rule (whether in the State of New York or any other jurisdiction) that would cause the application of the
laws of any jurisdiction other than the State of New York. In furtherance of the foregoing, the internal law of the State of New York will control the interpretation and construction of this Agreement, even if under such jurisdiction’s choice
of law or conflict of law analysis, the substantive law of some other jurisdiction would ordinarily or necessarily apply. 
  
 7. Notices. All notices, amendments, waivers, or other communications pursuant to this Agreement shall be in writing and shall be deemed to be
sufficient if delivered personally, telecopied, sent by e-mail, sent by nationally-recognized, overnight courier or mailed by registered or certified mail (return receipt requested), postage prepaid, to the parties at the following addresses (or at
such other address for a party as shall be specified by like notice): 
  

			
	If to Cooper:	  	If to Duska:
		
	CooperSurgical, Inc.	  	Duska Scientific Co
	95 Corporate Drive	  	Two Bala Plaza, Suite 300
	Trumbull, CT 06611	  	Bala Cynwyd, PA 19004
	Attn: Nicholas Pichotta, President	  	Attn: Dr. Amir Pelleg, President
	Fax: (203) 601-1008	  	Fax: (610) 660-0966
	e-mail: jim.posillico@coopersurgical.com	  	e-mail: pellega@duskascientific.com
		
	with a copy to:	  	 
		
	jennifer.kropitis@coopersurgieal.com	  	 

  
 All such notices and
other communications shall be deemed to have been delivered and received (i) in the case of personal delivery or delivery by telecopy or e-mail, on the date of such delivery if delivered during business hours on any day that is not a Saturday,
Sunday or a day on which banking institutions in New York, New York are not required to be open (“Business Day”) or, if not delivered during business hours on a Business Day, the first Business 

  

 5 

 
Day thereafter, (ii) in the case of delivery by nationally-recognized, overnight courier, on the Business Day following dispatch, and (iii) in the case of
mailing, on the fifth Business Day following such mailing. Copies of all notices and other communications delivered by telecopy or e-mail shall be sent by mail on the same day as they are telecopied or e-mailed. 
  
 8. Confidentiality. The confidentiality disclosure agreement dated
March 17, 2003 (the “Confidentiality Agreement”) between Cooper and Duska remains in effect. 
  
 9. Expenses. Except as otherwise set forth herein, each party shall be responsible for all costs and expenses incurred by it in connection with
this Agreement. 
  
 10. Counterparts. This Agreement may be
executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Facsimile counterpart signatures to this Agreement shall be acceptable and binding. 

 
 11. Exercise of Rights. No single or partial, exercise or waiver of
any right, power or option under this Agreement shall preclude any other or further exercise thereof or the exercise or waiver of any other right, power or option. No delay or omission on the part of Cooper or Duska in exercising any right, power or
option under this Agreement shall operate as a waiver of such right, power or option, or of any other right, power or option. 
  
 12. Successors and Assigns. This Agreement shall inure to the benefit of Cooper and Duska and their successors and assigns. Neither party shall be
entitled to assign its rights or obligations hereunder without the prior written consent of the other party, provided that Cooper or Duska (subject to Section 1(a)) may assign this Agreement without such consent to any of its affiliates or in
connection with a merger or consolidation or sale of all or substantially all the assets of such assigning party. Notwithstanding any other provisions of this Agreement, Duska may not assign this Agreement without the prior written consent of Cooper
to any of the companies listed on Exhibit 3 or any affiliates of such companies, except that, if Cooper and Duska have not entered into a Proposed Transaction prior to the end of the Exclusivity Period, such an assignment is permitted without
Cooper’s prior written consent. In the event of an assignment of this Agreement under the preceding sentence to any of the companies listed on Exhibit 3 or any affiliates of such companies, Cooper shall have no obligation to provide Media under
Section 5(a) to any such assignee of this Agreement. 
  
 13.
Severability. Any provision in this Agreement which is illegal, invalid or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such illegality, invalidity or unenforceability without invalidating
the remaining provisions hereof or affecting the legality, validity or enforceability of such provision in any other jurisdiction. The parties hereto agree to negotiate in good faith to replace any illegal, invalid or unenforceable provision of this
Agreement with a legal, valid and enforceable provision that, to the extent possible, will preserve the economic bargain of this Agreement or otherwise to amend this Agreement to achieve such result. 
  
 14. Headings. The captions set forth in this Agreement are for
convenience only and shall not be considered as part of this Agreement or as in any way limiting or amplifying the terms and provisions hereof. 
  

 6 

 15. Entire Agreement. This Agreement constitutes the entire understanding and agreement of the
parties with respect to the subject matter of this Agreement, and any and all prior agreements (except for the Confidentiality Agreement) are hereby terminated and canceled in their entirety and are of no further force or effect. 
  
 16. Modification or Amendment. No amendment, change or modification of
this Agreement shall be valid unless in writing and signed by Cooper and Duska. 
  
 If the foregoing reflects our agreement, please so indicate by signing below. 
  

									
	 	 	 	 	 Very truly yours,

			
	 	 	 	 	 COOPERSURGICAL, INC.

					
	 	 	 	 	 	 	 By:
	 	 /s/ James Posillico

	 	 	 	 	 	 	 	 	 James Posillico, Chief Scientific Officer

			
	 ACCEPTED AND AGREED
 this ____ day of April,
2004
	 	 	 	 
			
	DUSKA SCIENTIFIC CO.	 	 	 	 
					
	 By:
	 	 /s/ Amir Pelleg, Ph.D.
	 	 	 	 	 	 
	 	 	 Amir Pelleg, Ph.D., President
	 	 	 	 	 	 

  

 7 

 EXHIBIT 1 
  

Certain Definitions 
  
 For purposes of this Agreement: 
  
 “Intellectual Property Rights” means and includes all intellectual property rights, including without limitation, all patents, patent rights (including but not limited to the patent applications
listed below, and any and all continuations, divisions, reissues, re-examinations or extensions thereof), trademarks, trade names, trade styles, service marks, copyrights and any applications for any of the foregoing, trade secrets, proprietary
processes and information, designs, formulae, techniques, inventions and other know-how, proprietary technology, computer programs and software (including, without limitation, all source code, object code, user manuals, specifications, instructions,
programming notes and other documentation related thereto), databases, logos, manufacturing information, mask works, moral rights, and all other rights relating to intellectual property whether statutory or based in common law, and the goodwill
associated therewith. 
  
 “Person” shall be construed broadly and
shall include an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization or another entity including a governmental entity (or any
department, agency or political subdivision thereof). 
  
 “Product” means a product which is based on the Technology and which is capable of carrying out the Applications. 
  
 “Technology” means all of the Intellectual Property Rights in and to Duska’s AT PotentTM technology and any other products, methods, procedures and techniques to enhance the acrosome reaction of human and animal sperm in-vitro and to enhance the
overall fertilization capacity of human and animal sperm both in-vitro and in-vivo, whether or not in existence as of the date of this Agreement, including without limitation, all improvements, derivatives and modifications thereto. 
  
 Duska Patents/Patent Applications 
  

							
	 Application No.

	  	 Title

	  	 Priority Date

	  	 Country

	 5,474,890
	  	Method for Inducing the Acrosome Reaction in Human and Animal Spermatozoa	  	Issued December 12, 1995	  	US
				
	 Application No.

	  	 Title

	  	 Priority Date

	  	 Country

	 666,011
	  	Method for Inducing the Acrosome Reaction in Human and Animal Spermatozoa	  	Issued June 8, 1993	  	Australia

  

 8 

 EXHIBIT 2 
  

Non-Binding Indicative Business Terms 
  

			
	Basic Transaction	  	Cooper’s acquisition of an exclusive worldwide license for the Technology for use in applications in the human reproductive and animal husbandry markets for a term ending on expiration of
the last expiring key patent on the Technology. In addition to the terms set forth in this Exhibit 2. the definitive agreements shall include terms and conditions customary in a transaction of this sort.
		
	License Payment	  	Amount to be discussed.
		
	Royalty	  	Amount to be discussed.
		
	Minimum Sales	  	The parties shall negotiate annual and aggregate minimum sale requirements for the Product, including Cooper’s right to cure any failure to meet an annual minimum sale requirement. The sole
consequence of Cooper’s failure to meet an annual minimum sale requirement will be to make the license permanently non-exclusive thereafter so that Duska can directly and/or through one or more third party contractors or licensees market the
Product.
		
	Phase II/III Clinical Trials	  	Duska and Cooper will coordinate Phase II/III clinical trials and other FDA requirements, including, without limitation, the preparation and submission of a New Drug Approval application
(“NDA”) to the FDA for marketing approval for the Product. Cooper shall be responsible for the direct expenses incurred in connection with actually conducting Phase II/III clinical trials (including, without limitation, the costs of
investigators and investigative sites, the enrollment of patients in the trial, FDA consultants hired by Cooper, the preparation of protocols, the submission of Phase II/III related reports to the FDA and Cooper’s communications with the FDA)
and Duska shall be responsible for all other costs associated with FDA requirements, including, without limitation, FDA consultant fees, travel expenses, preparation of the NDA and its submission to the FDA). Each party shall provide the other party
with access to such available information, materials and personnel as the other party may require for the coordination and carrying out of Phase II/III clinical trials, including, without limitation, the preparation and submission of the
NDA.
		
	Supplies	  	Duska will sell to Cooper clinical and commercial supplies of the ATPotentTM formulation to meet Cooper’s supply requirements on mutually agreeable terms and conditions. Those terms shall

  

 9 

			
	 	  	include the possible use of alternate sources of supply if, but only if, Duska is unable or unwilling to meet Cooper’s requirements or the parties, after negotiating in good faith, are
unable to agree on sale terms for the supplies.
		
	Next Generation Product	  	Following the commercial launch of the Product, if Cooper and Duska agree, they shall work together to develop and commercialize a second generation, proprietary version of the Product which
will be jointly owned by them. Any second generation Product based on Duska’s “ATP Forte” technology is excluded from the preceding sentence.
		
	Non-Competition and Consulting Agreements	  	Duska will agree not to compete with the Product or other products carrying out the Applications during the term of the license and to consult with Cooper concerning Technology enhancements
during the same period. During the term of the license, Cooper will not market any competing product that is based on the delivery of compounds which enhance the acrosome reaction specifically through the P2 receptor and the related intracellular,
biochemical pathway to which it is linked.
		
	Indemnities	  	Duska will make customary representations and warranties with respect to the Technology, including, without limitation, non-infringement, and shall indemnify Cooper for breaches thereof up to a
cap equal to the aggregate amount of royalties Cooper would otherwise pay Duska for the Technology. Cooper will make customary representations and warranties with respect to the Media, including, without limitation, non-infringement, and shall
indemnify Duska for breaches thereof up to a reasonable cap thereon to be agreed by the parties.

  
 * * * * 
  

 10 

 EXHIBIT 3 
  

			
	1.	  	Vitrolife AB
		
	2.	  	Irvine Scientific
		
	3.	  	Medi-cult
		
	4.	  	VitroCare
		
	5.	  	Conception Technologies
		
	6.	  	Nidacon
		
	7.	  	FertiPro

  

 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]